Partial
Not Aligned
Patient Risk:
Moderate
Summary
Many mechanistic, indication, and common adverse-reaction claims are not verifiable from the provided label excerpts; several drug-interaction and epidemiology-style claims (e.g., exact incidence, % increase, specific interactions with ibuprofen/naproxen/aspirin/opioids) are not supported by the provided prescribing information and therefore are unsupported. Some safety elements (rhabdomyolysis rarity/seriousness, myopathy/rhabdomyolysis risk with certain drugs, diarrhea/nausea/myalgia) align broadly with the label excerpts.
Category Scores
Accurate Statements
Lipitor has been shown to be effective in reducing the risk of heart attacks.
Section 1.1 indicates reducing risk of myocardial infarction.
Lipitor has been shown to be effective in reducing the risk of strokes.
Section 1.1 indicates reducing risk of stroke.
Lipitor can cause muscle pain or weakness.
Section 6.1 lists myalgia as a common adverse reaction; Section 5.1 discusses myopathy.
Lipitor can cause nausea or vomiting.
Section 6.1 lists nausea as a common adverse reaction; vomiting is not explicitly listed in provided excerpts.
Lipitor can cause diarrhea.
Section 6.1 lists diarrhea as a common adverse reaction.
Taking Lipitor with certain pain medications can increase the risk of muscle damage (rhabdomyolysis).
Section 5.1 states concomitant use with certain drugs increases risk of myopathy/rhabdomyolysis.
Rhabdomyolysis is a serious condition that occurs when muscle tissue breaks down and releases muscle fibers into the bloodstream.
Section 5.1/6.2 mention rhabdomyolysis and its association with acute renal failure; the provided excerpts do not define the mechanism in this exact wording.
Unsupported Statements
Lipitor (atorvastatin) is a statin medication that works by inhibiting the production of cholesterol in the liver.
Mechanism is not described in the provided excerpts in terms of 'inhibiting the production of cholesterol in the liver' (though label excerpt 12.1 indicates inhibition of HMG-CoA reductase).
Lipitor is commonly prescribed to individuals with high cholesterol, heart disease, or those at risk of developing these conditions.
The provided label excerpts describe indications/usage criteria but do not support 'commonly prescribed' or 'high cholesterol' phrasing.
Lipitor has been shown to be effective in reducing the risk of other cardiovascular events.
Section 1.1 supports reductions in revascularization/angina and CHF hospitalization, but the generic claim about 'other cardiovascular events' is not directly supported as written.
Lipitor can cause headaches.
Headache is not listed in the provided adverse reaction excerpts.
Lipitor can cause dizziness or lightheadedness.
Dizziness/lightheadedness is not listed in the provided adverse reaction excerpts.
Lipitor can cause abdominal pain.
Abdominal pain is not listed in the provided adverse reaction excerpts.
Lipitor can cause fatigue.
Fatigue is not listed in the provided adverse reaction excerpts.
Lipitor can cause sleep disturbances.
Sleep disturbances are not listed in the provided adverse reaction excerpts.
Rhabdomyolysis can lead to kidney damage.
The label excerpt states acute renal failure secondary to myoglobinuria; it does not explicitly say 'kidney damage' in those terms.
Rhabdomyolysis can lead to kidney failure.
Acute renal failure is mentioned, but 'kidney failure' is not explicitly stated in the provided excerpt.
Rhabdomyolysis can lead to death.
Fatal outcome is not mentioned in the provided excerpts.
According to the FDA, rhabdomyolysis is a rare but serious side effect of Lipitor.
The label excerpt calls rhabdomyolysis 'rare cases' and reports acute renal failure; provided excerpts do not include the phrase 'rare but serious' nor attribute to 'According to the FDA' as written.
The risk of rhabdomyolysis is higher when Lipitor is taken with NSAIDs like ibuprofen or naproxen.
Provided label excerpts list increased myopathy risk with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, protease inhibitors, itraconazole); no NSAID/ibuprofen/naproxen association is provided.
Ibuprofen taken with Lipitor can increase the risk of kidney damage.
Not supported by provided label excerpts.
Naproxen taken with Lipitor can increase the risk of kidney damage.
Not supported by provided label excerpts.
Aspirin taken with Lipitor can increase the risk of kidney damage.
Not supported by provided label excerpts.
Opioids such as oxycodone and hydrocodone can increase the risk of respiratory depression when taken with Lipitor.
No opioid/respiratory depression interaction is described in the provided label excerpts.
A study in the Journal of Clinical Pharmacology found that taking Lipitor with ibuprofen increased the risk of rhabdomyolysis by 50%.
Not supported by provided label excerpts (and specific percent increase and journal citation are not present).
A study in the Journal of Clinical Pharmacology reported that after taking Lipitor and ibuprofen together, 12 patients developed rhabdomyolysis out of 1,000 patients.
Not supported by provided label excerpts.
Patients taking Lipitor should avoid taking Lipitor with NSAIDs or opioids unless absolutely necessary.
The provided label excerpts do not instruct avoidance with NSAIDs or opioids; only caution with certain drug classes (statins with fibrates generally; strong CYP3A4 inhibitors; cyclosporine dose limitation) is provided.
Patients taking Lipitor should monitor for muscle pain or weakness and report changes to their doctor.
The provided excerpts describe myopathy/rhabdomyolysis risk and liver function testing, but do not include this monitoring instruction.
Patients should not stop taking Lipitor without consulting their doctor.
Discontinuation counseling is not present in the provided label excerpts.
Contradictions
Important Omissions
Pregnancy/nursing contraindication: Lipitor is contraindicated in women who are pregnant or may become pregnant, and women requiring treatment should not breastfeed.
Importance:
High
Contraindications: active liver disease and hypersensitivity are contraindications.
Importance:
Moderate
Label-specific guidance on liver function testing prior to and at 12 weeks after initiation and after dose increases.
Importance:
Moderate
Dose timing/admin details: Lipitor can be administered once daily at any time of day, with or without food; no such administration details are provided by the AI response.
Importance:
Low
Drug interaction details specified in label for strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors) and cyclosporine dose limitation.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported interaction claims (NSAIDs/ibuprofen/naproxen/aspirin/opioids with specific outcomes) and missing label contraindications (pregnancy, nursing, active liver disease) could mislead decision-making and increase avoidable risk relative to the provided label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported drug-interaction claims (NSAIDs/ibuprofen/naproxen/aspirin/opioids; quantitative study findings) and omission of key label contraindications and interaction precautions (pregnancy/nursing; strong CYP3A4 inhibitors; cyclosporine dosing limits).
Suggested Improvement
Restrict interaction and risk statements to those explicitly supported by the provided label excerpts (e.g., risk with cyclosporine and strong CYP3A4 inhibitors; fibrate caution). Include key contraindications (pregnancy/may become pregnant; nursing; active liver disease) and label-directed monitoring (liver function tests per label). Remove unverifiable quantitative and journal-specific claims not present in the provided prescribing information.